Revolution Medicines: Buy Rating Backed by Promising RASolute 302 Trial and Potential Stock Surge
I'm PortAI, I can summarize articles.
Analyst Charles Zhu from LifeSci Capital maintains a Buy rating on Revolution Medicines with a $104 price target, driven by the promising RASolute 302 trial for daraxonrasib in pancreatic cancer. The trial's success could significantly impact the stock, potentially increasing its value by 60%. Zhu, a 5-star analyst, highlights the trial's potential to change clinical practices and its promising progression-free survival and overall survival trends.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments